Abstract
The role of p38 mitogen-activated protein (MAP) kinase, and extracellular-regulated protein kinase -1 and -2 in regulating constitutive apoptosis and interleukin (IL)-5-induced survival of human eosinophils have been investigated. Two populations of donors were identified whose eosinophils, in the absence of exogenous cytokines, underwent apoptosis at different rates. Eosinophils were thus arbitrarily classified as either “fast”- or “slow”-dying cells, where greater or less than 15% of the cells were apoptotic at 2 days, respectively. The selective p38 MAP kinase inhibitor, SB 203580, increased constitutive eosinophil apoptosis in both populations (EC50 ∼2 μM) as evinced from morphological analysis, flow cytometry, and DNA laddering. The ability of SB 203580 to kill eosinophils was not due to nonspecific toxicity or through the inhibition of prostanoid or leukotriene production. Exposure of eosinophils to IL-5, at a concentration (10 pM) that enhanced survival maximally, abolished SB 203580-induced apoptosis. In contrast PD 098059, which selectively blocks MAP kinase kinase (MEK) 1, did not affect apoptosis of fast- or slow-dying eosinophils, or the enhanced survival of cells effected by IL-5. Collectively, these results suggest that: 1) the basal activity of p38 MAP kinase may regulate the survival of cytokine-deprived eosinophils through inhibition of apoptosis, 2) the enhancement of eosinophil survival effected by IL-5 is mediated by a mechanism(s) divorced from the activation of p38 MAP kinase, and 3) neither spontaneous eosinophil apoptosis nor their enhanced survival by IL-5 involves the activation of MEK-1.
Footnotes
-
Send reprint requests to: Dr. Mark A. Lindsay, Thoracic Medicine, National Heart & Lung Institute, Imperial College of Science, Technology & Medicine, Dovehouse Street, London SW3 6LY, UK. E-mail:m.lindsay{at}i.c.ac.uk
-
↵1 This work was supported by the Academy of Finland, the Medical Research Council (MRC) (UK), British Lung Foundation (BLF) and the Wellcome Trust (UK) Grant 056814.
-
↵2 Medical School/B, University of Tampere, P.O. Box 607 FIN-33101, Tampere, Finland.
- Abbreviations:
- IL
- interleukin
- ERK
- extracellular-regulated kinase
- MAP
- mitogen-activated protein
- MEK
- mitogen-activated protein kinase kinase
- JNK
- c-jun N-terminal kinase
- TNF-α
- tumor necrosis factor-α
- FCS
- fetal calf serum
- PI
- propidium iodide
- TBS-T
- 25 mM Tris base, 150 mM NaCl, 0.1% Tween 20, pH 7.4
- ECL
- enhanced chemiluminescence
- Received December 17, 1998.
- Accepted April 21, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|